ArticleCancer immunology, immunotherapy : CII2022

Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma.

Chwee Ming Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.